A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease
- Focus Adverse reactions
- 19 Jul 2017 Planned End Date changed from 1 Nov 2019 to 1 Jul 2019.
- 19 Jul 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Jul 2019.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.